The Potential Cost-Effectiveness of a Cell-Based Bioelectronic Implantable Device Delivering Interferon- β1a Therapy Versus Injectable Interferon-β1a Treatment in Relapsing–Remitting Multiple Sclerosis
ConclusionInnovative technology such as the Optoferon implant may be a cost-effective therapy for patients with MS. The novel implantable mode of therapeutic protein administration has the potential to become a new mode of treatment administration for MS patients and in other disease areas. However, trials are needed to establish safety and effectiveness.
Source: PharmacoEconomics - Category: Health Management Source Type: research
More News: Avonex | Disability | Health Management | Multiple Sclerosis | Netherlands Health | Opthalmology | Rebif | Study